<DOC>
	<DOCNO>NCT02443831</DOCNO>
	<brief_summary>This study aim evaluate safety , efficacy duration response CD19 Chimeric Antigen Receptor ( CAR ) redirect autologous T-cells child high risk , relapse CD19+ haematological malignancy .</brief_summary>
	<brief_title>CARPALL : Immunotherapy With CD19 CAR T-cells CD19+ Haematological Malignancies</brief_title>
	<detailed_description>This multi-centre , non-randomised , open label Phase I clinical trial Advanced Therapy Investigational Medicinal Product name CD19 Chimeric Antigen Receptor ( CAR ) T-cells ( CD19 CAR T-cells ) child young adult ( age &lt; 24 year ) high risk , relapse CD19+ haematological malignancy ( Acute Lymphoblastic Leukemia Burkitt 's lymphoma ) . Following informed consent registration trial , patient undergo unstimulated leukapheresis generation CD19 CAR T-cells . Patients receive CD19CAR T-cells follow lymphodepleting chemotherapy . The study evaluate safety , efficacy duration response CD19 CAR T-cells child high risk relapse CD19+ malignancy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Children young adult ( age 24 year young ) high risk/relapsed CD19+ haematological malignancy : 1 . Resistant disease ( &gt; 25 % blast ) end UKALL 2011 equivalent induction 2 . ALL persistent high level MRD 2nd time point frontline national protocol ( currently &gt; 5 x 103 week 14 UKALL2011 equivalent ) 3 . High risk infant ALL ( age &lt; 6 month diagnosis MLL gene rearrangement either present white cell count &gt; 300 x 109/L poor steroid early response ( i.e circulate blast count &gt; 1x109/L follow 7 day steroid prephase Interfant 06 ) 4 . Intermediate risk infant ALL MRD &gt; 103 end Interfant06 induction 5 . Very early ( &lt; 18 month diagnosis ) bone marrow extramedullary relapse acute lymphoblastic leukaemia ( ALL ) 6 . Early ( within 6 month finish therapy ) bone marrow , combine extramedullary relapse ALL bone marrow minimal residual disease ( MRD ) &gt; 103 end reinduction 7 . Any therapy relapse ALL patient age 1624 8 . Any relapse infant ALL 9 . ALL post ≥ 2nd relapse 10 . Any refractory relapse ALL 11 . ALL MRD &gt; 104 prior plan stem cell transplant 12 . Any relapse ALL eligible stem cell transplant available HLA match donor contraindication transplant 13 . Any relapse ALL stem cell transplant 14 . Any relapse Burkitt 's CD19+ lymphoma 2 . Agreement pregnancy test , use adequate contraception ( applicable ) 3 . Written inform consent Exclusion Criteria registration : 1 . CD19 negative disease 2 . Active hepatitis B , C HIV infection 3 . Oxygen saturation ≤ 90 % air 4 . Bilirubin &gt; 3 x upper limit normal 5 . Creatinine &gt; 3 x upper limit normal 6 . Women pregnant lactate 7 . Stem Cell Transplant patient : active acute graftversushost disease ( GVHD ) overall Grade ≥ II ( Seattle criterion ) moderate/severe chronic GVHD ( NIH consensus criterion ) require systemic steroid 8 . Inability tolerate leucapheresis 9 . Karnofsky ( age ≥ 10 year ) Lansky ( age &lt; 10 ) score ≤ 50 % Exclusion criterion CD19CAR Tcell infusion : 1 . Severe intercurrent infection time schedule CD19CAR Tcell infusion 2 . Requirement supplementary oxygen active pulmonary infiltrates time schedule CD19CAR Tcell infusion 3 . Allogeneic transplant recipient active acute GVHD overall grade &gt; 2 moderate/severe chronic GVHD require systemic steroid time schedule CD19CAR Tcell infusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>high risk relapse CD19+ hematological malignancy</keyword>
</DOC>